A Phase I/II study of AZD0305 for Relapsed/Refractory Multiple Myeloma

Study identifier:D7230C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Refractory Multiple Myeloma

Medical condition

Multiple Myeloma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD0305

Sex

All

Estimated Enrollment

64

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 01 Dec 2023
Estimated Primary Completion Date: 07 Nov 2025
Estimated Study Completion Date: 07 Nov 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria